Extended Data Figure 5: RapaLink-1 is a potent mTOR inhibitor in wild-type and mutant mTOR cells.
From: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
a–d, MCF-7, RR1, RR2 and TKi-R cells were treated with different concentrations of rapamycin (a), MLN0128 (b), combination treatment (c) or RapaLink-1 (d) over 3 days. The cell growth was determined as described in Fig. 1d. Each dot and error bar on the curves represents mean ± s.d. (n = 8).
